{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:46Z","timestamp":1786982746338,"version":"build-2736575974"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40257-020-00579-z","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T19:28:28Z","timestamp":1609788508000},"page":"139-147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-\u03b1 Inhibitors?"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7033-4725","authenticated-orcid":false,"given":"Tasnim","family":"Abdalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4256-478X","authenticated-orcid":false,"given":"Michelle A.","family":"Lowes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8243-2071","authenticated-orcid":false,"given":"Nirmal","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2517-7008","authenticated-orcid":false,"given":"Robert G.","family":"Micheletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7794-6150","authenticated-orcid":false,"given":"A. Hillary","family":"Steinhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1171-4917","authenticated-orcid":false,"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,5]]},"reference":[{"key":"579_CR1","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1016\/j.jaad.2015.07.053","volume":"73","author":"RA Lee","year":"2015","unstructured":"Lee RA, Eisen DB. Treatment of hidradenitis suppurativa with biologic medications. J Am Acad Dermatol. 2015;73:S82\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2015.07.053.","journal-title":"J Am Acad Dermatol."},{"key":"579_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/jdv.15233","volume":"33","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization: systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33:19\u201331. https:\/\/doi.org\/10.1111\/jdv.15233.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"579_CR3","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504370.","journal-title":"N Engl J Med."},{"issue":"1","key":"579_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/jdv.15940","volume":"34","author":"N Kirsten","year":"2020","unstructured":"Kirsten N, Petersen J, Hagenstr\u00f6m K, Augustin M. Epidemiology of hidradenitis suppurativa in Germany: an observational cohort study based on a multisource approach. J Eur Acad Dermatol Venereol. 2020;34(1):174\u20139.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"3","key":"579_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jaad.2012.07.027","volume":"68","author":"I Cosmatos","year":"2013","unstructured":"Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68(3):412\u20139.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"579_CR6","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jaad.2008.06.020","volume":"59","author":"JE Revuz","year":"2008","unstructured":"Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59(4):596\u2013601.","journal-title":"J Am Acad Dermatol."},{"issue":"2 Pt 1","key":"579_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0190-9622(96)90321-7","volume":"35","author":"GB Jemec","year":"1996","unstructured":"Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35(2 Pt 1):191\u20134.","journal-title":"J Am Acad Dermatol."},{"key":"579_CR8","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jaad.2015.07.052","volume":"73","author":"GBE Jemec","year":"2015","unstructured":"Jemec GBE, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol. 2015;73:S4\u20137.","journal-title":"J Am Acad Dermatol."},{"key":"579_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41702-019-0052-0","volume":"4","author":"K Phan","year":"2020","unstructured":"Phan K, Charlton O, Smith SD. Global prevalence of hidradenitis suppurativa and geographical variation: systematic review and meta-analysis. Biomed Dermatol. 2020;4:2. https:\/\/doi.org\/10.1186\/s41702-019-0052-0.","journal-title":"Biomed Dermatol."},{"key":"579_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/bjd.12104","volume":"168","author":"JL Blok","year":"2013","unstructured":"Blok JL, van Hattem S, Jonkman MF, Horv\u00e1th B. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168:243\u201352. https:\/\/doi.org\/10.1111\/bjd.12104.","journal-title":"Br J Dermatol."},{"key":"579_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2040622319851640","volume":"10","author":"KT Savage","year":"2019","unstructured":"Savage KT, Flood KS, Porter ML, Kimball AB. TNF-\u03b1 inhibitors in the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis. 2019;10:1\u201312. https:\/\/doi.org\/10.1177\/2040622319851640.","journal-title":"Ther Adv Chronic Dis."},{"key":"579_CR12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","volume":"157","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157:846\u201355. https:\/\/doi.org\/10.7326\/0003-4819-157-12-201212180-00004.","journal-title":"Ann Intern Med."},{"key":"579_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","volume":"62","author":"A Grant","year":"2010","unstructured":"Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205\u201317. https:\/\/doi.org\/10.1016\/j.jaad.2009.06.050.","journal-title":"J Am Acad Dermatol."},{"key":"579_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/jdv.13216","volume":"30","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30:989\u201394. https:\/\/doi.org\/10.1111\/jdv.13216.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"579_CR15","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/bjd.13270","volume":"171","author":"AB Kimball","year":"2014","unstructured":"Kimball AB, Jemec GBE, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171:1434\u201342. https:\/\/doi.org\/10.1111\/bjd.13270.","journal-title":"Br J Dermatol."},{"key":"579_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00575-3","author":"T Abdalla","year":"2020","unstructured":"Abdalla T, Mansour M, Bouazzi D, Lowes MA, Jemec GBE, Alavi A. Therapeutic drug monitoring in patients with suboptimal response to adalimumab for hidradenitis suppurativa: a retrospective case series. Am J Clin Dermatol. 2020. https:\/\/doi.org\/10.1007\/s40257-020-00575-3.","journal-title":"Am J Clin Dermatol."},{"key":"579_CR17","first-page":"201","volume":"15","author":"K Bendtzen","year":"2013","unstructured":"Bendtzen K. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. Discov Med. 2013;15:201\u201311.","journal-title":"Discov Med."},{"key":"579_CR18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/bjd.17641","volume":"181","author":"ARJV Vossen","year":"2019","unstructured":"Vossen ARJV, Ardon CB, van der Zee HH, Lubberts E, Prens EP. The anti-inflammatory potency of biologics targeting tumour necrosis factor-\u03b1, interleukin (IL)-17A, IL-12\/23 and CD20 in hidradenitis suppurativa: an ex vivo study. Br J Dermatol. 2019;181:314\u201323. https:\/\/doi.org\/10.1111\/bjd.17641.","journal-title":"Br J Dermatol."},{"key":"579_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jaad.2019.05.094","volume":"82","author":"J Bagel","year":"2020","unstructured":"Bagel J, Lebwohl M, Israel RJ, Jacobson A. Immunogenicity and skin clearance recapture in clinical studies of brodalumab. J Am Acad Dermatol. 2020;82:344\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2019.05.094.","journal-title":"J Am Acad Dermatol."},{"key":"579_CR20","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1002\/jcph.1474","volume":"59","author":"J Zhou","year":"2019","unstructured":"Zhou J, Limsakun T, Yin O, et al. First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of an oral formulation of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects. J Clin Pharmacol. 2019;59:1669\u201377. https:\/\/doi.org\/10.1002\/jcph.1474.","journal-title":"J Clin Pharmacol."},{"key":"579_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/cei.13261","volume":"196","author":"S Mojtahed Poor","year":"2019","unstructured":"Mojtahed Poor S, Ulsh\u00f6fer T, Gabriel LA, et al. Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab. Clin Exp Immunol. 2019;196:259\u201375. https:\/\/doi.org\/10.1111\/cei.13261.","journal-title":"Clin Exp Immunol."},{"key":"579_CR22","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40262-016-0502-4","volume":"56","author":"A Nader","year":"2017","unstructured":"Nader A, Beck D, Noertersheuser P, Williams D, Mostafa N. Population pharmacokinetics and immunogenicity of adalimumab in adult patients with moderate-to-severe hidradenitis suppurativa. Clin Pharmacokinet. 2017;56:1091\u2013102. https:\/\/doi.org\/10.1007\/s40262-016-0502-4.","journal-title":"Clin Pharmacokinet."},{"key":"579_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, Schneider-Burrus S, Szepietowski JC, Zee HH, et al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619\u201344. https:\/\/doi.org\/10.1111\/jdv.12966.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"579_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","volume":"366","author":"GBE Jemec","year":"2012","unstructured":"Jemec GBE. Hidradenitis suppurativa. N Engl J Med. 2012;366:158\u201364. https:\/\/doi.org\/10.1056\/NEJMcp1014163.","journal-title":"N Engl J Med."},{"key":"579_CR25","doi-asserted-by":"publisher","first-page":"e0195325","DOI":"10.1371\/journal.pone.0195325","volume":"13","author":"M Liu","year":"2018","unstructured":"Liu M, Degner J, Davis JW, Idler KB, Nader A, Mostafa NM, et al. Identification of HLA-DRB1 association to adalimumab immunogenicity. PLoS ONE. 2018;13:e0195325. https:\/\/doi.org\/10.1371\/journal.pone.0195325.","journal-title":"PLoS ONE"},{"key":"579_CR26","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/bjd.17695","volume":"181","author":"JW Frew","year":"2019","unstructured":"Frew JW, Hawkes JE, Sullivan-Whalen M, Gilleaudeau P, Krueger JG. Inter-rater reliability of phenotypes and exploratory genotype\u2013phenotype analysis in inherited hidradenitis suppurativa. Br J Dermatol. 2019;181:566\u201371. https:\/\/doi.org\/10.1111\/bjd.17695.","journal-title":"Br J Dermatol."},{"key":"579_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00504-4","author":"EP Prens","year":"2020","unstructured":"Prens EP, Lugo-Somolinos AM, Paller AS, Kerdel F, Duan Y, Teixeira HD, et al. Baseline characteristics from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa (acne inversa) in clinical practice. Am J Clin Dermatol. 2020. https:\/\/doi.org\/10.1007\/s40257-020-00504-4.","journal-title":"Am J Clin Dermatol."},{"key":"579_CR28","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.12688\/f1000research.11337.1","volume":"6","author":"MK Smith","year":"2017","unstructured":"Smith MK, Nicholson CL, Parks-Miller A, Hamzavi IH. Hidradenitis suppurativa: an update on connecting the tracts. F1000Res. 2017;6:1272. https:\/\/doi.org\/10.12688\/f1000research.11337.1.","journal-title":"F1000Res."},{"key":"579_CR29","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","volume":"139","author":"E Witte-H\u00e4ndel","year":"2019","unstructured":"Witte-H\u00e4ndel E, Wolk K, Tsaousi A, et al. The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J Investig Dermatol. 2019;139:1294\u2013305. https:\/\/doi.org\/10.1016\/j.jid.2018.11.018.","journal-title":"J Investig Dermatol."},{"key":"579_CR30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2018;113:481\u2013517. https:\/\/doi.org\/10.1038\/ajg.2018.27.","journal-title":"Am J Gastroenterol."},{"key":"579_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/1756283X08092548","volume":"1","author":"GR Lichtenstein","year":"2008","unstructured":"Lichtenstein GR, Panaccione R, Mallarkey G. Efficacy and safety of adalimumab in Crohn\u2019s disease. Ther Adv Gastroenterol. 2008;1:43\u201350. https:\/\/doi.org\/10.1177\/1756283X08092548.","journal-title":"Ther Adv Gastroenterol."},{"key":"579_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","volume":"126","author":"J-F Colombel","year":"2004","unstructured":"Colombel J-F, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19\u201331. https:\/\/doi.org\/10.1053\/j.gastro.2003.10.047.","journal-title":"Gastroenterology"},{"key":"579_CR33","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/ibd\/izx072","volume":"24","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, et al. Infliximab for Crohn\u2019s disease: more than 13 years of real-world experience. Inflamm Bowel Dis. 2018;24:490\u2013501. https:\/\/doi.org\/10.1093\/ibd\/izx072.","journal-title":"Inflamm Bowel Dis."},{"key":"579_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.10.024","author":"A Gottlieb","year":"2020","unstructured":"Gottlieb A, Natsis NE, Kerdel F, et al. A phase II open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain. J Investig Dermatol. 2020. https:\/\/doi.org\/10.1016\/j.jid.2019.10.024.","journal-title":"J Investig Dermatol."},{"key":"579_CR35","doi-asserted-by":"publisher","first-page":"j2505","DOI":"10.1136\/bmj.j2505","volume":"357","author":"BL Cohen","year":"2017","unstructured":"Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505. https:\/\/doi.org\/10.1136\/bmj.j2505.","journal-title":"BMJ"},{"key":"579_CR36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","volume":"80","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, Okun MM, Prens EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80:60\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2018.05.040.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"579_CR37","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jaad.2019.09.071","volume":"82","author":"MH Ghias","year":"2020","unstructured":"Ghias MH, Johnston AD, Kutner AJ, Micheletti RG, Hosgood HD, Cohen SR. High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa. J Am Acad Dermatol. 2020;82(5):1094\u2013101. https:\/\/doi.org\/10.1016\/j.jaad.2019.09.071.","journal-title":"J Am Acad Dermatol."},{"key":"579_CR38","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/bjd.17537","volume":"180","author":"JR Ingram","year":"2018","unstructured":"Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa). Br J Dermatol. 2018;180:1009\u201317. https:\/\/doi.org\/10.1111\/bjd.17537.","journal-title":"Br J Dermatol."},{"key":"579_CR39","unstructured":"HUMIRA (adalimumab) [package insert]. North Chicago (IL): Abb-Vie Inc.; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125057s409lbl.pdf. Accessed 05 Dec 2020."},{"issue":"5","key":"579_CR40","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/jdv.16023","volume":"34","author":"H van der Zee","year":"2020","unstructured":"van der Zee H, Longcore M, Geng Z, Garg A. Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials. J Eur Acad Dermatol Venereol. 2020;34(5):1050\u20136. https:\/\/doi.org\/10.1111\/jdv.16023.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"579_CR41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1208\/s12248-019-0363-5","volume":"21","author":"Y Bi","year":"2019","unstructured":"Bi Y, Liu J, Wang J, Epps RE, Kettl D, et al. Model-informed drug development approach supporting approval of adalimumab (HUMIRA) in adolescent patients with hidradenitis suppurativa: a regulatory perspective. AAPS J. 2019;21:91. https:\/\/doi.org\/10.1208\/s12248-019-0363-5.","journal-title":"AAPS J."},{"key":"579_CR42","unstructured":"National Institute for Clinical Excellence. Adalimumab for treating moderate to severe hidradenitis suppurativa. London: NICE; 2016. Technology appraisal no. 392.\u00a0https:\/\/www.nice.org.uk\/guidance\/ta392. Accessed 22 Feb 2020."},{"issue":"S2","key":"579_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/exd.13893","volume":"28","author":"W Gulliver","year":"2019","unstructured":"Gulliver W. Plenary lecture: updated medical treatments of hidradenitis suppurativa, more options, less evidence. Exp Dermatol. 2019;28(S2):5\u201355. https:\/\/doi.org\/10.1111\/exd.13893.","journal-title":"Exp Dermatol."},{"key":"579_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/exd.13893","volume":"28","author":"F Alfageme","year":"2019","unstructured":"Alfageme F. Plenary lectures: intensification strategies 80 mg weekly with adalimumab in HS: when and what for? Exp Dermatol. 2019;28:5\u201355.","journal-title":"Exp Dermatol."},{"key":"579_CR45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/jdv.12438","volume":"29","author":"G Martin-Ezquerra","year":"2015","unstructured":"Martin-Ezquerra G, Masferrer E, Masferrer-Niub\u00f2 M, Ferran M, S\u00e1nchez-Rega\u00f1a M, Collgros H, et al. Use of biological treatments in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29:56\u201360.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"1","key":"579_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000503606","volume":"236","author":"CC Zouboulis","year":"2020","unstructured":"Zouboulis CC, Hansen H, Caposiena Caro RD, Damiani G, Delorme I, Pascual JC, et al. Adalimumab dose intensification in recalcitrant hidradenitis suppurativa\/acne inversa. Dermatology (Basel). 2020;236(1):25\u201330. https:\/\/doi.org\/10.1159\/000503606.","journal-title":"Dermatology (Basel)."},{"issue":"3","key":"579_CR47","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jaad.2019.05.022","volume":"81","author":"AN Oskardmay","year":"2019","unstructured":"Oskardmay AN, Miles JA, Sayed CJ. Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2019;81(3):702\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2019.05.022.","journal-title":"J Am Acad Dermatol."},{"key":"579_CR48","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/bjd.12713","volume":"170","author":"B Moriarty","year":"2014","unstructured":"Moriarty B, Jiyad Z, Creamer D. Four-weekly infliximab in the treatment of severe hidradenitis suppurativa. Br J Dermatol. 2014;170:986\u20137.","journal-title":"Br J Dermatol."},{"key":"579_CR49","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","volume":"153","author":"JD Feuerstein","year":"2017","unstructured":"Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S, American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153:827\u201334.","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"579_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bjd.12366","volume":"169","author":"Z Laftah","year":"2013","unstructured":"Laftah Z, Arkir Z, Agius E, Desai N. Abstract of \"Main plenary session: infliximab for hidradenitis suppurativa; should we be measuring antibody levels?\" Br J Dermatol. 2013;169(Suppl. 1): 1-7.\u00a0https:\/\/doi.org\/10.1111\/bjd.12366.","journal-title":"Br J Dermatol"},{"key":"579_CR51","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jaad.2019.09.012","volume":"82","author":"LL Wang","year":"2020","unstructured":"Wang LL, Micheletti RG. Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: a retrospective chart review. J Am Acad Dermatol. 2020;82:507\u201310. https:\/\/doi.org\/10.1016\/j.jaad.2019.09.012.","journal-title":"J Am Acad Dermatol."},{"key":"579_CR52","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","volume":"17","author":"K Papamichael","year":"2019","unstructured":"Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1655\u201368. https:\/\/doi.org\/10.1016\/j.cgh.2019.03.037.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"522\u201330","key":"579_CR53","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.cgh.2014.07.029","volume":"13","author":"H Yanai","year":"2015","unstructured":"Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13(522\u201330):522\u201330. https:\/\/doi.org\/10.1016\/j.cgh.2014.07.029.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"579_CR54","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","volume":"137","author":"K Karmiris","year":"2009","unstructured":"Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn\u2019s disease. Gastroenterology. 2009;137:1628\u201340. https:\/\/doi.org\/10.1053\/j.gastro.2009.07.062.","journal-title":"Gastroenterology"},{"key":"579_CR55","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","volume":"4","author":"EA Maser","year":"2006","unstructured":"Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2006;4:1248\u201354. https:\/\/doi.org\/10.1016\/j.cgh.2006.06.025.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"579_CR56","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1365-2036.2008.03828.x","volume":"28","author":"RL West","year":"2008","unstructured":"West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PCF, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn\u2019s disease. Aliment Pharmacol Ther. 2008;28:1122\u20136. https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03828.x.","journal-title":"Aliment Pharmacol Ther."},{"key":"579_CR57","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/apt.12869","volume":"40","author":"Y Mazor","year":"2014","unstructured":"Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn\u2019s disease. Aliment Pharmacol Ther. 2014;40:620\u20138. https:\/\/doi.org\/10.1111\/apt.12869.","journal-title":"Aliment Pharmacol Ther."},{"key":"579_CR58","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1\u2013106. https:\/\/doi.org\/10.1136\/gutjnl-2019-318484.","journal-title":"Gut"},{"key":"579_CR59","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/apt.14368","volume":"46","author":"N Mitrev","year":"2017","unstructured":"Mitrev N, Van de Casteele N, Seow CH, IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46:1037\u201353. https:\/\/doi.org\/10.1111\/apt.14368.","journal-title":"Aliment Pharmacol Ther"},{"key":"579_CR60","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/ajg.2010.9","volume":"105","author":"W Afif","year":"2010","unstructured":"Afif W, Loftus EV, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133\u20139. https:\/\/doi.org\/10.1038\/ajg.2010.9.","journal-title":"Am J Gastroenterol."},{"key":"579_CR61","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/apt.14124","volume":"46","author":"MG Ward","year":"2017","unstructured":"Ward MG, Warner B, Unsworth N, et al. Infliximab and adalimumab drug levels in Crohn\u2019s disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther. 2017;46:150\u201361. https:\/\/doi.org\/10.1111\/apt.14124.","journal-title":"Aliment Pharmacol Ther."},{"key":"579_CR62","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","volume":"148","author":"NV Casteele","year":"2015","unstructured":"Casteele NV, Ferrante M, Assche GV, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2015.02.031.","journal-title":"Gastroenterology"},{"key":"579_CR63","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1053\/j.gastro.2019.06.003","volume":"157","author":"A Assa","year":"2019","unstructured":"Assa A, Matar M, Turner D, et al. Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn\u2019s disease compared with reactive monitoring. Gastroenterology. 2019;157:985\u201396. https:\/\/doi.org\/10.1053\/j.gastro.2019.06.003.","journal-title":"Gastroenterology"},{"key":"579_CR64","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/ibd\/izz131","volume":"26","author":"SR Fernandes","year":"2020","unstructured":"Fernandes SR, Bernardo S, Sim\u00f5es C, et al. Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease. Inflamm Bowel Dis. 2020;26:263\u201370. https:\/\/doi.org\/10.1093\/ibd\/izz131.","journal-title":"Inflamm Bowel Dis."},{"key":"579_CR65","doi-asserted-by":"publisher","first-page":"014581","DOI":"10.1136\/bmjopen-2016-014581","volume":"7","author":"K Freeman","year":"2017","unstructured":"Freeman K, Taylor-Phillips S, Connock M, et al. Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn\u2019s disease: a systematic review and meta-analysis. BMJ Open. 2017;7:014581. https:\/\/doi.org\/10.1136\/bmjopen-2016-014581.","journal-title":"BMJ Open."},{"key":"579_CR66","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/apt.14318","volume":"46","author":"H Nakase","year":"2017","unstructured":"Nakase H, Motoya S, Matsumoto T, DIAMOND Study Group, et al. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn\u2019s disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther. 2017;46:873\u201382. https:\/\/doi.org\/10.1111\/apt.14318.","journal-title":"Aliment Pharmacol Ther"},{"key":"579_CR67","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CLM, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460\u20138. https:\/\/doi.org\/10.1001\/jama.2011.406.","journal-title":"JAMA"},{"key":"579_CR68","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00535-013-0803-4","volume":"49","author":"H Imaeda","year":"2014","unstructured":"Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn\u2019s disease. J Gastroenterol. 2014;49:100\u20139. https:\/\/doi.org\/10.1007\/s00535-013-0803-4.","journal-title":"J Gastroenterol."},{"key":"579_CR69","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrgastro.2013.253","volume":"11","author":"S Ben-Horin","year":"2014","unstructured":"Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 2014;11:243\u201355. https:\/\/doi.org\/10.1038\/nrgastro.2013.253.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"579_CR70","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1097\/MIB.0000000000000772","volume":"22","author":"C Steenholdt","year":"2016","unstructured":"Steenholdt C, Bendtzen K, Brynskov J, et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis. 2016;22:1999\u20132015. https:\/\/doi.org\/10.1097\/MIB.0000000000000772.","journal-title":"Inflamm Bowel Dis"},{"key":"579_CR71","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/jcag\/gwy009.157","volume":"1","author":"TA Cookson","year":"2018","unstructured":"Cookson TA, Fedorak R, Halloran BP, et al. A157: the threshold for infliximab trough levels leading to dose escalation differs between Crohn\u2019s disease and ulcerative colitis. J Can Assoc Gastroenterol. 2018;1:233\u20134. https:\/\/doi.org\/10.1093\/jcag\/gwy009.157.","journal-title":"J Can Assoc Gastroenterol"},{"key":"579_CR72","doi-asserted-by":"publisher","first-page":"e019909","DOI":"10.1136\/bmjopen-2017-019909","volume":"8","author":"A Johnston","year":"2018","unstructured":"Johnston A, Natarajan S, Hayes M, et al. Accelerated induction regimens of TNF-alpha inhibitors in patients with inflammatory bowel disease: a scoping review protocol. BMJ Open. 2018;8:e019909. https:\/\/doi.org\/10.1136\/bmjopen-2017-019909.","journal-title":"BMJ Open."},{"key":"579_CR73","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.cgh.2014.07.041","volume":"13","author":"DJ Gibson","year":"2015","unstructured":"Gibson DJ, Heetun ZS, Redmond CE, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:330\u20135. https:\/\/doi.org\/10.1016\/j.cgh.2014.07.041.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"579_CR74","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jid.2018.07.028","volume":"139","author":"N Wilkinson","year":"2019","unstructured":"Wilkinson N, Tsakok T, Dand N, BSTOP Study Group PSORT Consortium, et al. Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study. J Investig Dermatol. 2019;139:115\u201323. https:\/\/doi.org\/10.1016\/j.jid.2018.07.028.","journal-title":"J Investig Dermatol"},{"key":"579_CR75","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1001\/jamadermatol.2014.5479","volume":"151","author":"SP Menting","year":"2015","unstructured":"Menting SP, Coussens E, Pouw MF, et al. Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: a step toward personalized treatment. JAMA Dermatol. 2015;151:616\u201322. https:\/\/doi.org\/10.1001\/jamadermatol.2014.5479.","journal-title":"JAMA Dermatol"},{"key":"579_CR76","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/bjd.18016","volume":"182","author":"N Van den Berghe","year":"2020","unstructured":"Van den Berghe N, den Keyser ED, Soenen R, et al. Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis. Br J Dermatol. 2020;182:390\u20137. https:\/\/doi.org\/10.1111\/bjd.18016.","journal-title":"Br J Dermatol."},{"key":"579_CR77","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/j.jid.2019.04.012","volume":"139","author":"R Soenen","year":"2019","unstructured":"Soenen R, Meulewaeter E, Grine L, et al. Defining a minimal effective serum trough concentration of secukinumab in psoriasis: a step toward personalized therapy. J Investig Dermatol. 2019;139:2232\u20133223. https:\/\/doi.org\/10.1016\/j.jid.2019.04.012.","journal-title":"J Investig Dermatol."},{"key":"579_CR78","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/cts.12725","volume":"13","author":"S Pan","year":"2020","unstructured":"Pan S, Tsakok T, Dand N, BADBIR Study Group, the BSTOP Study Group, the PSORT Consortium, et al. Using real-world data to guide ustekinumab dosing strategies for psoriasis: a prospective pharmacokinetic-pharmacodynamic study. Clin Transl Sci. 2020;13:400\u20139. https:\/\/doi.org\/10.1111\/cts.12725.","journal-title":"Clin Transl Sci."},{"key":"579_CR79","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1346-8138.2012.01679.x","volume":"40","author":"H Takahashi","year":"2013","unstructured":"Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol. 2013;40:39\u201342. https:\/\/doi.org\/10.1111\/j.1346-8138.2012.01679.x.","journal-title":"J Dermatol."},{"key":"579_CR80","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1725369","author":"S Tourdot","year":"2020","unstructured":"Tourdot S, Abdolzade-Bavil A, Bessa J, et al. 10th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals. mAbs. 2020. https:\/\/doi.org\/10.1080\/19420862.2020.1725369.","journal-title":"mAbs"},{"key":"579_CR81","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40259-019-00355-4","volume":"33","author":"S Bellinvia","year":"2019","unstructured":"Bellinvia S, Cummings JRF, Ardern-Jones MR, Edwards CJ. Adalimumab biosimilars in Europe: an overview of the clinical evidence. BioDrugs. 2019;33:241\u201353. https:\/\/doi.org\/10.1007\/s40259-019-00355-4.","journal-title":"BioDrugs."},{"key":"579_CR82","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/14740338.2019.1602117","volume":"18","author":"G Murdaca","year":"2019","unstructured":"Murdaca G, Negrini S, Greco M, Schiavi C, Giusti F, Borro M, et al. Immunogenicity of infliximab and adalimumab. Expert Opin Drug Saf. 2019;18:343\u20135. https:\/\/doi.org\/10.1080\/14740338.2019.1602117.","journal-title":"Expert Opin Drug Saf."},{"key":"579_CR83","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/annrheumdis-2015-208684","volume":"75","author":"MB Ruiz-Arg\u00fcello","year":"2016","unstructured":"Ruiz-Arg\u00fcello MB, Maguregui A, Ruiz Del Agua A, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016;75:1693\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208684.","journal-title":"Ann Rheum Dis."},{"key":"579_CR84","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.det.2015.08.006","volume":"34","author":"HH van der Zee","year":"2016","unstructured":"van der Zee HH, Gulliver WP. Medical treatments of hidradenitis suppurativa: more options, less evidence. Dermatol Clin. 2016;34:91\u20136. https:\/\/doi.org\/10.1016\/j.det.2015.08.006.","journal-title":"Dermatol Clin."},{"key":"579_CR85","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40265-015-0516-5","volume":"76","author":"IE Deckers","year":"2016","unstructured":"Deckers IE, Prens EP. An update on medical treatment options for hidradenitis suppurativa. Drugs. 2016;76:215\u201329. https:\/\/doi.org\/10.1007\/s40265-015-0516-5.","journal-title":"Drugs."},{"key":"579_CR86","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/09546634.2017.1395806","volume":"29","author":"M Maarouf","year":"2018","unstructured":"Maarouf M, Clark AK, Lee DE, Shi VY. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatol Treat. 2018;29:441\u20139. https:\/\/doi.org\/10.1080\/09546634.2017.1395806.","journal-title":"J Dermatol Treat."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00579-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-020-00579-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00579-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T02:02:43Z","timestamp":1654394563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-020-00579-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["579"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00579-z","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,5]]},"assertion":[{"value":"5 January 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors received no financial support for the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Afsaneh Alavi has acted as a consultant, advisor, and\/or received research funding from Abbvie, Galderma, Janssen, LEO Pharma, Novartis, Sanofi Aventis, Valeant, Boehringer-Ingelheim, DSBiopharma, Eli Lilly, Glenmark, Incyte, Ilkos, Merck Serono, Pfizer, Regeneron, Roche, Xenon, and Xoma. Michelle A. Lowes has served on the advisory boards for Abbvie, Janssen, and Viela Bio, and consulted for Almirall, BSN, Incyte, Janssen, Kymera, and Xbiotech. Tasnim Abdalla, Robert\u00a0G. Micheletti, and Nirmal\u00a0Kaur have no conflicts of interest that are directly relevant to the content of this article. A. Hillary Steinhart has acted as a consultant, advisor and\/or received research funding from Abbvie, Janssen, Merck, Pfizer, Roche, Arena Pharmaceuticals, Celgene, Takeda, RedHill Biopharma, and Nubiyota.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Afsaneh Alavi conceived the idea for the article. Tasnim Abdalla performed the literature search and data analysis. The first draft of the manuscript was written by Tasnim Abdalla and all authors contributed to writing, reviewing, and critically revising previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}